TRPC5 and breast carcinoma: This scenario is supported by the observations that HDMECs exposed to TRPC5-contanining EVs, which were collected from adriamycin MCF-7 breast cancer cells, over-expressed the TRPC3-NFATc3-P-gp signaling pathway and developed resistance to adriamycin-induced apoptosis [104].